Chemoradiotherapy programs with cisplatin and etoposide ( [ VP-16 ] PE ) and simultaneous chest RT produce grade 4 neutropenia and thrombocytopenia in a small-enough proportion of patients that prophylactic hematopoietic growth factors are clinically unnecessary .
